CTLA4 and neoplasm: In an EMT-6 tumor xenograft model, the NPs combined with free anti-CTLA-4 were able to decrease tumor mass by ~80%, in contrast to ~60% decrease without CTLA-4 antibody, and ~40% with nab-paclitaxel only (38).